Pharmacokinetics of Posaconazole Administered Orally or by Nasogastric Tube in Healthy Volunteers

Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commerc...

Full description

Saved in:

Bibliographic Details
Published in	Antimicrobial Agents and Chemotherapy Vol. 53; no. 7; pp. 2960 - 2964
Main Authors	DODDS ASHLEY, Elizabeth S, VARKEY, Jay B, KRISHNA, Gopal, VICKERY, Donna, LEI MA, XIN YU, MALAVADE, Darshana, GOODWIN, Megan, PERFECT, John R, POWER, Eddie
Format	Journal Article
Language	English
Published	Washington, DC American Society for Microbiology 01.07.2009 American Society for Microbiology (ASM)
Subjects	Administration, Oral Adolescent Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antifungal Agents Antifungal Agents - administration & dosage Antifungal Agents - pharmacokinetics Biological and medical sciences Cross-Over Studies Female Humans Intubation, Gastrointestinal Male Medical sciences Middle Aged Pharmacology Pharmacology. Drug treatments Triazoles Triazoles - administration & dosage Triazoles - pharmacokinetics Young Adult Human Antifungal agent Tube Healthy subject Azole derivatives Nasogastric Oral administration Triazole derivatives Pharmacokinetics Posaconazole
Online Access	Get full text

Cover

Loading…

Abstract	Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy AAC RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0066-4804 Online ISSN: 1098-6596 Copyright © 2014 by the American Society for Microbiology. For an alternate route to AAC .asm.org, visit: AAC
AbstractList	The use of a nasogastric tube is one means of administering antifungal therapy to critically ill patients unable to receive medication via the oral route. This was a phase 1, open-label, single-center, randomized, crossover study of posaconazole administered via nasogastric tube in healthy volunteers. Each subject received two 400-mg single doses of posaconazole, one administered orally and one administered by nasogastric tube, with a 7-day washout period between each dose. Posaconazole was administered 5 to 10 min after subjects received a nutritional supplement. Blood samples for pharmacokinetic analysis were obtained up to 120 h postdose. The analysis of variance estimate of the study population suggests that the posaconazole nasogastric tube administration least-square mean values of observed maximum concentration ( C max ), area under the plasma concentration-time curve (AUC) to the last measurable concentration, and AUC to time infinity were 81%, 76%, and 77%, respectively, of the corresponding oral administration values. The reason for lower C max and AUC values when posaconazole is administered via the nasogastric tube route is not known. Oral and nasogastric tube administration of a single 400-mg dose of posaconazole suspension was safe and well tolerated in healthy adult subjects. The incidence and nature of treatment-emergent adverse events were similar with both administration routes, and no serious adverse events or clinically significant laboratory test or vital sign abnormalities were reported. Obtaining plasma posaconazole concentrations may be warranted when posaconazole is given to patients via a nasogastric tube to ensure adequate posaconazole exposure. Strategies that have been shown to enhance posaconazole exposure (such as splitting the dose and minimizing the use of proton pump inhibitors) may also be used. The use of a nasogastric tube is one means of administering antifungal therapy to critically ill patients unable to receive medication via the oral route. This was a phase 1, open-label, single-center, randomized, crossover study of posaconazole administered via nasogastric tube in healthy volunteers. Each subject received two 400-mg single doses of posaconazole, one administered orally and one administered by nasogastric tube, with a 7-day washout period between each dose. Posaconazole was administered 5 to 10 min after subjects received a nutritional supplement. Blood samples for pharmacokinetic analysis were obtained up to 120 h postdose. The analysis of variance estimate of the study population suggests that the posaconazole nasogastric tube administration least-square mean values of observed maximum concentration (Cmax), area under the plasma concentration-time curve (AUC) to the last measurable concentration, and AUC to time infinity were 81%, 76%, and 77%, respectively, of the corresponding oral administration values. The reason for lower Cmax and AUC values when posaconazole is administered via the nasogastric tube route is not known. Oral and nasogastric tube administration of a single 400-mg dose of posaconazole suspension was safe and well tolerated in healthy adult subjects. The incidence and nature of treatment-emergent adverse events were similar with both administration routes, and no serious adverse events or clinically significant laboratory test or vital sign abnormalities were reported. Obtaining plasma posaconazole concentrations may be warranted when posaconazole is given to patients via a nasogastric tube to ensure adequate posaconazole exposure. Strategies that have been shown to enhance posaconazole exposure (such as splitting the dose and minimizing the use of proton pump inhibitors) may also be used. ABSTRACT The use of a nasogastric tube is one means of administering antifungal therapy to critically ill patients unable to receive medication via the oral route. This was a phase 1, open-label, single-center, randomized, crossover study of posaconazole administered via nasogastric tube in healthy volunteers. Each subject received two 400-mg single doses of posaconazole, one administered orally and one administered by nasogastric tube, with a 7-day washout period between each dose. Posaconazole was administered 5 to 10 min after subjects received a nutritional supplement. Blood samples for pharmacokinetic analysis were obtained up to 120 h postdose. The analysis of variance estimate of the study population suggests that the posaconazole nasogastric tube administration least-square mean values of observed maximum concentration ( C max ), area under the plasma concentration-time curve (AUC) to the last measurable concentration, and AUC to time infinity were 81%, 76%, and 77%, respectively, of the corresponding oral administration values. The reason for lower C max and AUC values when posaconazole is administered via the nasogastric tube route is not known. Oral and nasogastric tube administration of a single 400-mg dose of posaconazole suspension was safe and well tolerated in healthy adult subjects. The incidence and nature of treatment-emergent adverse events were similar with both administration routes, and no serious adverse events or clinically significant laboratory test or vital sign abnormalities were reported. Obtaining plasma posaconazole concentrations may be warranted when posaconazole is given to patients via a nasogastric tube to ensure adequate posaconazole exposure. Strategies that have been shown to enhance posaconazole exposure (such as splitting the dose and minimizing the use of proton pump inhibitors) may also be used. Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy AAC RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0066-4804 Online ISSN: 1098-6596 Copyright © 2014 by the American Society for Microbiology. For an alternate route to AAC .asm.org, visit: AAC The use of a nasogastric tube is one means of administering antifungal therapy to critically ill patients unable to receive medication via the oral route. This was a phase 1, open-label, single-center, randomized, crossover study of posaconazole administered via nasogastric tube in healthy volunteers. Each subject received two 400-mg single doses of posaconazole, one administered orally and one administered by nasogastric tube, with a 7-day washout period between each dose. Posaconazole was administered 5 to 10 min after subjects received a nutritional supplement. Blood samples for pharmacokinetic analysis were obtained up to 120 h postdose. The analysis of variance estimate of the study population suggests that the posaconazole nasogastric tube administration least-square mean values of observed maximum concentration (C(max)), area under the plasma concentration-time curve (AUC) to the last measurable concentration, and AUC to time infinity were 81%, 76%, and 77%, respectively, of the corresponding oral administration values. The reason for lower C(max) and AUC values when posaconazole is administered via the nasogastric tube route is not known. Oral and nasogastric tube administration of a single 400-mg dose of posaconazole suspension was safe and well tolerated in healthy adult subjects. The incidence and nature of treatment-emergent adverse events were similar with both administration routes, and no serious adverse events or clinically significant laboratory test or vital sign abnormalities were reported. Obtaining plasma posaconazole concentrations may be warranted when posaconazole is given to patients via a nasogastric tube to ensure adequate posaconazole exposure. Strategies that have been shown to enhance posaconazole exposure (such as splitting the dose and minimizing the use of proton pump inhibitors) may also be used.
Author	Gopal Krishna Eddie Power Donna Vickery Darshana Malavade John R. Perfect Elizabeth S. Dodds Ashley Jay B. Varkey Lei Ma Xin Yu Megan Goodwin
AuthorAffiliation	Duke University Medical Center, Durham, North Carolina, 1 Schering-Plough Research Institute, Kenilworth, New Jersey 2
AuthorAffiliation_xml	– name: Duke University Medical Center, Durham, North Carolina, 1 Schering-Plough Research Institute, Kenilworth, New Jersey 2
Author_xml	– sequence: 1 givenname: Elizabeth S surname: DODDS ASHLEY fullname: DODDS ASHLEY, Elizabeth S organization: Duke University Medical Center, Durham, North Carolina, United States – sequence: 2 givenname: Jay B surname: VARKEY fullname: VARKEY, Jay B organization: Duke University Medical Center, Durham, North Carolina, United States – sequence: 3 givenname: Gopal surname: KRISHNA fullname: KRISHNA, Gopal organization: Schering-Plough Research Institute, Kenilworth, New Jersey, United States – sequence: 4 givenname: Donna surname: VICKERY fullname: VICKERY, Donna organization: Schering-Plough Research Institute, Kenilworth, New Jersey, United States – sequence: 5 surname: LEI MA fullname: LEI MA organization: Schering-Plough Research Institute, Kenilworth, New Jersey, United States – sequence: 6 surname: XIN YU fullname: XIN YU organization: Schering-Plough Research Institute, Kenilworth, New Jersey, United States – sequence: 7 givenname: Darshana surname: MALAVADE fullname: MALAVADE, Darshana organization: Schering-Plough Research Institute, Kenilworth, New Jersey, United States – sequence: 8 givenname: Megan surname: GOODWIN fullname: GOODWIN, Megan organization: Duke University Medical Center, Durham, North Carolina, United States – sequence: 9 givenname: John R surname: PERFECT fullname: PERFECT, John R organization: Duke University Medical Center, Durham, North Carolina, United States – sequence: 10 givenname: Eddie surname: POWER fullname: POWER, Eddie organization: Schering-Plough Research Institute, Kenilworth, New Jersey, United States
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21719308$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19433558$$D View this record in MEDLINE/PubMed
BookMark	eNp1kcFvFCEUh4mpsdvqzbPBg01MnArDMDAXk81GrUlje9h4JW-YN7vUGWhhRrP968XupupBLgT48j3e-52QIx88EvKSs3POS_1-uVydM86VLph-QhacNbqoZVMfkQVjdV1UmlXH5CSlG5bPsmHPyDFvKiGk1AsC11uII9jw3XmcnE009PQ6pHzj4T4MSJfd6LxLE0bs6FWEYdjREGm7o18hhQ2kKTpL13OL1Hl6gTBM2x39FobZT4gxPSdPexgSvjjsp2T96eN6dVFcXn3-slpeFiCZmAoFqrbcYs2qspSYO6oVNG3NUSqsJZOi7LQAgdC3mkPb9RVTrLNa5WVBnJIPe-3t3I7YWfRT_qu5jW6EuDMBnPn3xbut2YQfplSsUoxlwdlBEMPdjGkyo0sWhwE8hjmZMg9bNlpm8N0etDGkFLF_LMKZ-R2JyZGYh0gM0xl_u8chjaW5CXP0eQz_Y1_93cQf8SGvDLw5AJAsDH0Eb1165EqueCMeRK_33NZttj9dRJOrGwBrpDDKlE3NxC878K74
CODEN	AACHAX
CitedBy_id	crossref_primary_10_1007_s11908_010_0133_0 crossref_primary_10_1002_ncp_10615 crossref_primary_10_1093_jpids_piw087 crossref_primary_10_1038_bmt_2010_185 crossref_primary_10_1128_AAC_01325_10 crossref_primary_10_1177_0148607116673053 crossref_primary_10_1128_AAC_00442_21 crossref_primary_10_4137_CMT_S1948 crossref_primary_10_1016_j_ejps_2016_05_009 crossref_primary_10_1345_aph_1Q456 crossref_primary_10_1128_AAC_05900_11 crossref_primary_10_1097_01_NURSE_0000437469_13218_7b crossref_primary_10_4081_pr_2011_e7 crossref_primary_10_1111_myc_13416 crossref_primary_10_1155_2014_146781 crossref_primary_10_1093_mmy_myu042 crossref_primary_10_1007_s40268_017_0178_8 crossref_primary_10_1080_14787210_2016_1207526 crossref_primary_10_1128_AAC_03777_14 crossref_primary_10_1128_AAC_06167_11 crossref_primary_10_4236_ajac_2015_612092 crossref_primary_10_1016_j_bbmt_2010_04_017 crossref_primary_10_1097_FTD_0b013e31821fb197 crossref_primary_10_1128_aac_01085_22 crossref_primary_10_1111_j_1439_0507_2010_01984_x crossref_primary_10_1111_jcpt_12483 crossref_primary_10_1093_jpids_piu019 crossref_primary_10_1128_AAC_00002_14 crossref_primary_10_1007_s00280_023_04612_w
Cites_doi	10.1007/s001340000771 10.1007/s10096-005-1325-7 10.1016/j.jpba.2006.06.011 10.2165/00003495-200565110-00007 10.1046/j.1365-2125.2003.01977.x 10.1086/503425 10.1128/AAC.00472-06 10.1179/joc.2006.18.4.445 10.1128/AAC.50.5.1881-1883.2006 10.2165/00003088-200544020-00006 10.1128/AAC.47.9.2788-2795.2003 10.1592/phco.27.12.1627 10.1093/jac/36.2.395 10.1128/AAC.50.1.126-133.2006 10.1128/AAC.47.10.3375.2003 10.1086/508774 10.1086/504328 10.1056/NEJMoa061098 10.1097/MCO.0b013e3280ef68cc 10.1128/AAC.01034-08 10.1056/NEJMoa061094 10.1086/500212
ContentType	Journal Article
Copyright	2009 INIST-CNRS Copyright © 2009 American Society for Microbiology Copyright © 2009, American Society for Microbiology
Copyright_xml	– notice: 2009 INIST-CNRS – notice: Copyright © 2009 American Society for Microbiology – notice: Copyright © 2009, American Society for Microbiology
DBID	IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T7 8FD C1K FR3 M7N P64 5PM
DOI	10.1128/AAC.01178-08
DatabaseName	Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Industrial and Applied Microbiology Abstracts (Microbiology A) Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts PubMed Central (Full Participant titles)
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Engineering Research Database Technology Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management
DatabaseTitleList	Engineering Research Database CrossRef MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Pharmacy, Therapeutics, & Pharmacology Biology
EISSN	1098-6596
EndPage	2964
ExternalDocumentID	10_1128_AAC_01178_08 1178-08 19433558 21719308 aac_53_7_2960
Genre	Clinical Trial, Phase I Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NCRR NIH HHS grantid: 5UL1RR024128-03 – fundername: NCRR NIH HHS grantid: UL1 RR024128
GroupedDBID	--- .55 .GJ 08R 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 AAPBV AAUGY ACGFO ADBBV AENEX AFMIJ AGNAY AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CS3 DIK E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 IQODW J5H K-O KQ8 L7B LSO MVM NEJ O9- OK1 P2P RHF RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZA5 ZGI ZXP ~A~ CGR CUY CVF ECM EIF NPM - 0R 55 A ABFLS ADACO ADBIT BXI GJ HZ AAYXX AGVNZ CITATION 7T7 8FD C1K FR3 M7N P64 5PM
ID	FETCH-LOGICAL-a503t-7a76c1ce604225e01167a9b61e57e650532d83a3eafb81abdf4070dc87777ca3
IEDL.DBID	RPM
ISSN	0066-4804
IngestDate	Tue Sep 17 21:23:01 EDT 2024 Fri Aug 16 23:20:44 EDT 2024 Thu Sep 12 17:51:09 EDT 2024 Tue Dec 28 13:59:19 EST 2021 Thu May 23 23:13:13 EDT 2024 Sun Oct 22 16:10:15 EDT 2023 Wed May 18 15:35:53 EDT 2016
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	7
Keywords	Human Antifungal agent Tube Healthy subject Azole derivatives Nasogastric Oral administration Triazole derivatives Pharmacokinetics Posaconazole
Language	English
License	CC BY 4.0
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-a503t-7a76c1ce604225e01167a9b61e57e650532d83a3eafb81abdf4070dc87777ca3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Corresponding author. Mailing address: Early Clinical Research and Experimental Medicine, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033. Phone and fax: (908) 740-6564. E-mail: gopal.krishna@spcorp.com
OpenAccessLink	https://europepmc.org/articles/pmc2704700?pdf=render
PMID	19433558
PQID	21285985
PQPubID	23462
PageCount	5
ParticipantIDs	proquest_miscellaneous_21285985 pascalfrancis_primary_21719308 crossref_primary_10_1128_AAC_01178_08 pubmed_primary_19433558 pubmedcentral_primary_oai_pubmedcentral_nih_gov_2704700 asm2_journals_10_1128_AAC_01178_08 highwire_asm_aac_53_7_2960
PublicationCentury	2000
PublicationDate	2009-07-01
PublicationDateYYYYMMDD	2009-07-01
PublicationDate_xml	– month: 07 year: 2009 text: 2009-07-01 day: 01
PublicationDecade	2000
PublicationPlace	Washington, DC
PublicationPlace_xml	– name: Washington, DC – name: United States
PublicationTitle	Antimicrobial Agents and Chemotherapy
PublicationTitleAbbrev	AAC
PublicationTitleAlternate	Antimicrob Agents Chemother
PublicationYear	2009
Publisher	American Society for Microbiology American Society for Microbiology (ASM)
Publisher_xml	– name: American Society for Microbiology – name: American Society for Microbiology (ASM)
References	8862212 - Am J Health Syst Pharm. 1996 Aug 15;53(16):1962 17024806 - J Chemother. 2006 Aug;18(4):445-6 11280621 - Intensive Care Med. 2001 Jan;27(1):115-21 19075045 - Antimicrob Agents Chemother. 2009 Mar;53(3):958-66 16705579 - Clin Infect Dis. 2006 Jun 15;42(12):1726-34 16377677 - Antimicrob Agents Chemother. 2006 Jan;50(1):126-33 12936975 - Antimicrob Agents Chemother. 2003 Sep;47(9):2788-95 14748822 - Br J Clin Pharmacol. 2004 Feb;57(2):218-22 16619151 - Clin Infect Dis. 2006 May 15;42(10):1398-403 15875225 - Eur J Clin Microbiol Infect Dis. 2005 May;24(5):358-60 17101682 - Antimicrob Agents Chemother. 2007 Feb;51(2):495-502 16511748 - Clin Infect Dis. 2006 Apr 1;42(7):e61-5 8522469 - J Antimicrob Chemother. 1995 Aug;36(2):395-401 17414496 - Curr Opin Clin Nutr Metab Care. 2007 May;10(3):284-90 16641468 - Antimicrob Agents Chemother. 2006 May;50(5):1881-3 17251530 - N Engl J Med. 2007 Jan 25;356(4):335-47 7473906 - J Trauma. 1995 Sep;39(3):445-7 15656699 - Clin Pharmacokinet. 2005;44(2):211-20 16033292 - Drugs. 2005;65(11):1553-67; discussion 1568-9 17143808 - Clin Infect Dis. 2007 Jan 1;44(1):2-12 18041883 - Pharmacotherapy. 2007 Dec;27(12):1627-36 16859858 - J Pharm Biomed Anal. 2007 Jan 4;43(1):228-36 14506064 - Antimicrob Agents Chemother. 2003 Oct;47(10):3375 9830458 - Strahlenther Onkol. 1998 Nov;174 Suppl 3:52-5 17251531 - N Engl J Med. 2007 Jan 25;356(4):348-59 e_1_3_2_26_2 (e_1_3_2_15_2) 1995; 36 (e_1_3_2_14_2) 2005; 24 e_1_3_2_21_2 e_1_3_2_22_2 e_1_3_2_23_2 e_1_3_2_24_2 e_1_3_2_25_2 (e_1_3_2_16_2) 1996; 53 (e_1_3_2_2_2) 2001; 27 e_1_3_2_9_2 e_1_3_2_7_2 e_1_3_2_18_2 e_1_3_2_19_2 (e_1_3_2_17_2) 1998; 174 (e_1_3_2_8_2) 2006; 18 (e_1_3_2_6_2) 2007; 10 e_1_3_2_10_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_3_2 e_1_3_2_13_2 (e_1_3_2_20_2) 1995; 39
References_xml	– volume: 27 start-page: 115 year: 2001 ident: e_1_3_2_2_2 publication-title: Intensive Care Med. doi: 10.1007/s001340000771 – volume: 24 start-page: 358 year: 2005 ident: e_1_3_2_14_2 publication-title: Eur. J. Clin. Microbiol. Infect. Dis. doi: 10.1007/s10096-005-1325-7 – ident: e_1_3_2_23_2 doi: 10.1016/j.jpba.2006.06.011 – ident: e_1_3_2_10_2 doi: 10.2165/00003495-200565110-00007 – ident: e_1_3_2_5_2 doi: 10.1046/j.1365-2125.2003.01977.x – ident: e_1_3_2_19_2 doi: 10.1086/503425 – ident: e_1_3_2_22_2 doi: 10.1128/AAC.00472-06 – volume: 18 start-page: 445 year: 2006 ident: e_1_3_2_8_2 publication-title: J. Chemother. doi: 10.1179/joc.2006.18.4.445 – ident: e_1_3_2_21_2 doi: 10.1128/AAC.50.5.1881-1883.2006 – volume: 39 start-page: 445 year: 1995 ident: e_1_3_2_20_2 publication-title: J. Trauma – ident: e_1_3_2_7_2 doi: 10.2165/00003088-200544020-00006 – ident: e_1_3_2_4_2 doi: 10.1128/AAC.47.9.2788-2795.2003 – ident: e_1_3_2_11_2 doi: 10.1592/phco.27.12.1627 – volume: 36 start-page: 395 year: 1995 ident: e_1_3_2_15_2 publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/36.2.395 – ident: e_1_3_2_9_2 doi: 10.1128/AAC.50.1.126-133.2006 – ident: e_1_3_2_13_2 doi: 10.1128/AAC.47.10.3375.2003 – volume: 174 start-page: 52 year: 1998 ident: e_1_3_2_17_2 publication-title: Strahlenther. Onkol. – ident: e_1_3_2_26_2 doi: 10.1086/508774 – volume: 53 start-page: 1962 year: 1996 ident: e_1_3_2_16_2 publication-title: Am. J. Health Syst. Pharm. – ident: e_1_3_2_18_2 doi: 10.1086/504328 – ident: e_1_3_2_24_2 doi: 10.1056/NEJMoa061098 – volume: 10 start-page: 284 year: 2007 ident: e_1_3_2_6_2 publication-title: Curr. Opin. Clin. Nutr. Metab. Care doi: 10.1097/MCO.0b013e3280ef68cc – ident: e_1_3_2_12_2 doi: 10.1128/AAC.01034-08 – ident: e_1_3_2_3_2 doi: 10.1056/NEJMoa061094 – ident: e_1_3_2_25_2 doi: 10.1086/500212
SSID	ssj0006590
Score	2.1482978
Snippet	Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... The use of a nasogastric tube is one means of administering antifungal therapy to critically ill patients unable to receive medication via the oral route. This... ABSTRACT The use of a nasogastric tube is one means of administering antifungal therapy to critically ill patients unable to receive medication via the oral...
SourceID	pubmedcentral proquest crossref asm2 pubmed pascalfrancis highwire
SourceType	Open Access Repository Aggregation Database Index Database Publisher
StartPage	2960
SubjectTerms	Administration, Oral Adolescent Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antifungal Agents Antifungal Agents - administration & dosage Antifungal Agents - pharmacokinetics Biological and medical sciences Cross-Over Studies Female Humans Intubation, Gastrointestinal Male Medical sciences Middle Aged Pharmacology Pharmacology. Drug treatments Triazoles Triazoles - administration & dosage Triazoles - pharmacokinetics Young Adult
Title	Pharmacokinetics of Posaconazole Administered Orally or by Nasogastric Tube in Healthy Volunteers
URI	http://aac.asm.org/content/53/7/2960.abstract https://www.ncbi.nlm.nih.gov/pubmed/19433558 https://journals.asm.org/doi/10.1128/AAC.01178-08 https://search.proquest.com/docview/21285985 https://pubmed.ncbi.nlm.nih.gov/PMC2704700
Volume	53
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwED6tk0C8oFF-ZYNiIdjT0jpxHKePVcU0gTaKVNDeLNt1RkWbTEv7EP56zkm8UgQvPCY5W06-s32XO38H8C5TSaRtzEPnKqODksehWqRJSDXLs7FRidFNtsVVevE1-XjNrw-A-7MwTdK-0cthsVoPi-X3Jrfydm1GPk9sNLucxoImgtJRD3qCMe-id8tvytsfK7iXhklGE5_tHmejyWQ6dBxojpO5YQtNmGMXx9VYVet4f2fybMEuWVJV-L3yttDF3yzRPxMqf9uhzo_gcWdakkn7Ck_gwBZ9eNAWm6z78PCyC6P34XTWElbXZ2S-O39VnZFTMttRWddPQfnLH9jOiZAyJ7OywjuF-lmuLPHku67kJ_mMo1rVpLwjuiZXqipvlCsLYsh8qy1ZFqQ99FSTb6jwiCians9gfv5hPr0Iu6IMoeKUbUKhRGoiY1NHHsZtE8dRY51GlguL5h5n8SJjilmV6yxSepGjy0gXxvEOCqPYczgsysK-BGJjtPZYmiu-oImJrM7RNGKRZTqJhKbjAN46WGQ3qSrZ-CtxJhFG2cAoaRbAew-avG35Of4hd-wRldirVMpIzqSQMbpwAQz2ML7vCf01NHBd6zcedInTz8VUVGHLbYUSjgEw4wG8aFVgN4pOuwIQe8pxL-CIvfefoL43BN-dfh__d8sTeNRGvVxa8Ss43Nxt7Ws0njZ6AL1PX7JBM2V-AZboF-M
link.rule.ids	230,315,733,786,790,891,27957,27958,53827,53829
linkProvider	National Library of Medicine
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFH4aQzAu_CgbdMBmIdhpSZM4TtJjVTEVWEsPZdrNsh0HqrXJtLSH7K_nOYlXOsEBjol_KE6-Z78Xf_4ewIdEhL7UAXNMqIwBShY4Io1Cx5M0S_pKhErWbItJNPoefrlklzvA7FmYmrSv5NzNF0s3n_-suZXXS9WzPLHedDwMYi-MPa_3AB6ivQaxDdLbCThiza8VXE2dMPFCy3cPkt5gMHSNCppRZa71QkNq9MVxPhblMthem6xesKFLihLfWNakuviTL3qfUvnbGnX2DC7s6BpqypW7XklX3d4Tfvzn4T-Hp63XSgZN8QvY0XkHHjV5LKsOPB63O_QdOJk2WtjVKZltjnaVp-SETDcq2dVLEPbyCtuZKqTIyLQo8U4ubouFJlbX12QTJd9wuIuKFDdEVmQiyuKHMBlHFJmtpSbznDTnqSpygbaEYEGvdh9mZ59mw5HT5ntwBPPoyolFHClf6cjokjFdbxGJvox8zWKNniSjQZpQQbXIZOILmWYYjXqpMpKGsRL0AHbzItevgegAHUkaZYKlXqh8LTP0uqivqQz9WHr9Lrw335u39lryOhQKEo744DU-uJd04aNFA79upD_-Uu_QQoVjr1wIxRnlMQ8wOuzC0RZ47nrCUBB9Z9P62KKJo2Wb7RqR62JdYg0jLpiwLrxqsLV5iha2XYi3UHdXwWiGb5cglmrt8BY7h__d8hj2RrPxOT__PPn6Bp40m2uGvfwWdlc3a_0OfbSVPKot8hfsLDja
linkToPdf	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lc9MwEN6BMnS4FAiUukCrYaCn-iX5lWMmkCmPhhwC0-GikWQZMk3sTJ0c3F_Pyo-m6cClR9srjWV_K-1an78FeJ-IwJeahrZJlTFByagt0iiwPcmypK9EoGTNthhHZz-CLxfhxa1SXzVpX8mZk88XTj77U3Mrlwvldjwxd3I-pLEXxJ7nLtPMfQiP0Gdpv0vU20k4CpvPK7ii2kHiBR3nnSbuYDB0jBKaUWauNUMDZjTGcU4W5YJur0-dZrChTIoSn1rWlLv4Vzx6l1Z5a50aPYVf3Qgbesqls15JR13fEX-81yN4Bntt9EoGjclzeKDzHjxu6llWPdg9b3fqe3AyaTSxq1My3fziVZ6SEzLZqGVXL0B0h5fYzpiQIiOTosQzubgu5pp0-r6mqij5jkOeV6S4IrIiY1EWv4WpPKLIdC01meWk-a-qIj_RpxA0GN2-hOno03R4Zrd1H2wRemxlxyKOlK90ZPTJQl1vFYm-jHwdxhojypDRNGGCaZHJxBcyzTAr9VJlpA1jJdg-7ORFrg-AaIoBJYsyEaZeoHwtM4y-mK-ZDPxYen0L3pl3zlu_LXmdEtGEI0Z4jRHuJRZ86BDBl40EyH_sDju4cOyVC6F4yHjMKWaJFhxtAeimJ0wJMYY2rY87RHH0cLNtI3JdrEu0MCKDSWjBqwZfm7tooWtBvIW8GwOjHb59BfFUa4i3-Dm8d8tj2J18HPFvn8dfX8OTZo_NkJjfwM7qaq3fYqi2kke1U_4Ftys7Wg
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+of+posaconazole+administered+orally+or+by+nasogastric+tube+in+healthy+volunteers&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Dodds+Ashley%2C+Elizabeth+S&rft.au=Varkey%2C+Jay+B&rft.au=Krishna%2C+Gopal&rft.au=Vickery%2C+Donna&rft.date=2009-07-01&rft.eissn=1098-6596&rft.volume=53&rft.issue=7&rft.spage=2960&rft_id=info:doi/10.1128%2FAAC.01178-08&rft_id=info%3Apmid%2F19433558&rft.externalDocID=19433558
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon